Skip to main content
Fig. 2 | Cost Effectiveness and Resource Allocation

Fig. 2

From: Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

Fig. 2

Deterministic sensitivity analysis and probabilistic sensitivity analysis results: Drivers of incremental cost per quality-adjusted life-year (QALY) gained for pemigatinib versus mFOLFOX a and 5-FU b. Incremental cost-effectiveness plane for pemigatinib versus mFOLFOX c and 5-FU d, and cost-effectiveness acceptance curve for pemigatinib versus mFOLFOX e and 5-FU f. Costs listed in 2022 NT dollars. The black lines indicate the willingness-to-pay threshold of NT$2,928,570 per QALY gained. WTP willingness to pay; EV expected value; ICER incremental cost-effectiveness ratio; mFOLFOX a combination of oxaliplatin, folinic acid, and fluorouracil; 5-FU fluorouracil; PD progressed disease, PF progression free; OS_pem_wshape shape parameter of overall survival (pemigatinib), OS_pem_wscale scale parameter of overall survival (pemigatinib), PFS_pem_scale scale parameter of progression-free survival (pemigatinib), OS_folfox_scale scale parameter of overall survival (mFOLFOX), PFS_pem_shape shape parameter of progression-free survival (pemigatinib), OS_folfox_shape shape parameter of overall survival (mFOLFOX), PFS_folfox_scale scale parameter of progression-free survival (mFOLFOX), PFS_folfox_shape shape parameter of progression-free survival (mFOLFOX), AE adverse event, OS_5fu_scale scale parameter of overall survival (5-FU), OS_5fu_shape shape parameter of overall survival (5-FU), PFS_5fu_scale scale parameter of progression-free survival (5-FU), PFS_5fu_shape shape parameter of progression-free survival (5-FU)

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us